Market Closed -
Nasdaq
02:00:01 04/05/2024 am IST
|
5-day change
|
1st Jan Change
|
2.05
USD
|
-3.76%
|
|
+6.22%
|
+45.39%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,223
|
441.2
|
234.1
|
343.2
|
-
|
-
|
Enterprise Value (EV)
1 |
861.6
|
183.2
|
72.97
|
286.4
|
174.9
|
77.4
|
P/E ratio
|
-6.31
x
|
-2.71
x
|
-5.64
x
|
-2.65
x
|
-2.66
x
|
-4.39
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
60
x
|
1,894
x
|
1,094
x
|
1,373
x
|
1,373
x
|
9.26
x
|
EV / Revenue
|
42.3
x
|
786
x
|
341
x
|
1,146
x
|
700
x
|
2.09
x
|
EV / EBITDA
|
-6.35
x
|
-1.27
x
|
-0.58
x
|
-2.39
x
|
-1.26
x
|
-0.47
x
|
EV / FCF
|
-13.6
x
|
-1.74
x
|
-0.86
x
|
-2.84
x
|
-1.56
x
|
-0.54
x
|
FCF Yield
|
-7.36%
|
-57.4%
|
-116%
|
-35.2%
|
-64.3%
|
-186%
|
Price to Book
|
3.25
x
|
1.69
x
|
0.96
x
|
2.56
x
|
1.65
x
|
1.32
x
|
Nbr of stocks (in thousands)
|
1,60,298
|
1,65,875
|
1,66,010
|
1,67,413
|
-
|
-
|
Reference price
2 |
7.630
|
2.660
|
1.410
|
2.050
|
2.050
|
2.050
|
Announcement Date
|
30/03/22
|
24/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.38
|
0.233
|
0.214
|
0.25
|
0.25
|
37.06
|
EBITDA
1 |
-135.8
|
-144.6
|
-125.2
|
-119.8
|
-138.4
|
-164
|
EBIT
1 |
-135.8
|
-144.8
|
-125.5
|
-135.1
|
-153.8
|
-137.5
|
Operating Margin
|
-666.49%
|
-62,140.34%
|
-58,631.31%
|
-54,034.27%
|
-61,536.07%
|
-370.98%
|
Earnings before Tax (EBT)
1 |
-136.6
|
-135.2
|
-39.29
|
-135.5
|
-153.6
|
-124.1
|
Net income
1 |
-167.8
|
-152.4
|
-40.22
|
-132.9
|
-150.6
|
-120.1
|
Net margin
|
-823.56%
|
-65,401.29%
|
-18,796.26%
|
-53,164%
|
-60,259.27%
|
-324.1%
|
EPS
2 |
-1.210
|
-0.9800
|
-0.2500
|
-0.7750
|
-0.7700
|
-0.4675
|
Free Cash Flow
1 |
-63.42
|
-105.2
|
-84.38
|
-100.8
|
-112.4
|
-144.1
|
FCF margin
|
-311.24%
|
-45,167.38%
|
-39,428.5%
|
-40,320%
|
-44,961.07%
|
-388.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/22
|
24/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.266
|
0.23
|
-
|
0.17
|
0.024
|
0.038
|
0.037
|
0.172
|
0.087
|
0.018
|
-
|
-
|
-
|
0.3
|
EBITDA
1 |
-33.37
|
-45.15
|
-33.38
|
-35.34
|
-38.39
|
-37.51
|
-33.15
|
-31.78
|
-26.76
|
-33.46
|
-29.55
|
-29.7
|
-30.35
|
-30.25
|
EBIT
1 |
-33.36
|
-45.18
|
-33.44
|
-35.36
|
-38.42
|
-37.56
|
-33.21
|
-31.86
|
-26.83
|
-33.56
|
-30.84
|
-33.08
|
-33.13
|
-34.86
|
Operating Margin
|
-12,541.73%
|
-19,641.3%
|
-
|
-20,798.24%
|
-1,60,095.83%
|
-98,855.26%
|
-89,767.57%
|
-18,524.42%
|
-30,843.68%
|
-1,86,450%
|
-
|
-
|
-
|
-11,619.07%
|
Earnings before Tax (EBT)
1 |
-26.47
|
-48.58
|
-31.92
|
-30.81
|
-33.13
|
-39.32
|
-33.16
|
-31.66
|
43.85
|
-18.32
|
-30.7
|
-33.16
|
-33.41
|
-35.16
|
Net income
1 |
-31.16
|
-88.88
|
-36.87
|
-36.62
|
-33.89
|
-45.01
|
-33.14
|
-33.04
|
44.24
|
-18.29
|
-30
|
-32.38
|
-32.63
|
-34.31
|
Net margin
|
-11,713.53%
|
-38,642.17%
|
-
|
-21,540%
|
-1,41,195.83%
|
-1,18,450%
|
-89,554.05%
|
-19,210.47%
|
50,855.17%
|
-1,01,622.22%
|
-
|
-
|
-
|
-11,435.13%
|
EPS
2 |
-0.2100
|
-0.6200
|
-0.2400
|
-0.2400
|
-0.2200
|
-0.2800
|
-0.2100
|
-0.2100
|
0.2500
|
-0.1200
|
-0.1820
|
-0.1960
|
-0.1940
|
-0.1900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
30/03/22
|
16/05/22
|
15/08/22
|
10/11/22
|
24/03/23
|
11/05/23
|
10/08/23
|
14/11/23
|
28/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
362
|
258
|
161
|
56.8
|
168
|
266
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-63.4
|
-105
|
-84.4
|
-101
|
-112
|
-144
|
ROE (net income / shareholders' equity)
|
-71.8%
|
-47.8%
|
-16%
|
-59.1%
|
-58.1%
|
-45.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
2.350
|
1.570
|
1.460
|
0.8000
|
1.240
|
1.550
|
Cash Flow per Share
2 |
-0.4600
|
-0.6700
|
-0.5300
|
-0.3800
|
-0.3700
|
-0.4000
|
Capex
1 |
0.17
|
0.77
|
0.26
|
3.5
|
3.21
|
3.92
|
Capex / Sales
|
0.85%
|
331.76%
|
121.03%
|
1,400%
|
1,285.87%
|
10.58%
|
Announcement Date
|
30/03/22
|
24/03/23
|
28/03/24
|
-
|
-
|
-
|
Last Close Price
2.05
USD Average target price
11.8
USD Spread / Average Target +475.61% Consensus |
1st Jan change
|
Capi.
|
---|
| +45.39% | 343M | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|